Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug750 | COVID-19 PCR and Serology Wiki | 0.71 |
| drug2713 | Opt-in Recruitment Email Wiki | 0.71 |
| drug843 | Cannabidivarin Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D002659 | Child Development Disorders, Pervasive NIH | 0.29 |
| D001321 | Autistic Disorder NIH | 0.21 |
| D000067877 | Autism Spectrum Disorder NIH | 0.19 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000717 | Autism HPO | 0.21 |
| HP:0000729 | Autistic behavior HPO | 0.19 |
Navigate: Correlations HPO
There are 2 clinical trials
This trial aims to study the efficacy and safety of cannabidivarin (CBDV) in children with ASD.
Description: Change in ABC-I from Baseline to Endpoint
Measure: Aberrant Behavior Checklist-Irritability Subscale (ABC-I) Time: Change in ABC-I from Baseline to Week 12 (Change over 12 weeks)Description: Change in RBS-R from Baseline to Endpoint
Measure: Repetitive Behavior Scale-Revised (RBS-R) Time: Change in RBS-R from Baseline to Week 12 (Change over 12 weeks)Description: Change in ABC-SW from Baseline to Endpoint
Measure: Aberrant Behavior Checklist-Social Withdrawal Subscale (ABC-SW) Time: Change in ABC-SW from Baseline to Week 12 (Change over 12 weeks)Description: Change in PedsQL from Baseline to Endpoint
Measure: Pediatric Quality of Life Inventory (PedsQL) Family Impact Module Time: Change in PedsQL from Baseline to Week 12 (Change over 12 weeks)Description: Change in Vineland-3 from Baseline to Endpoint
Measure: Vineland Adaptive Behavior Scale-3 (Vineland 3) Time: Change in Vineland-3 from Baseline to Week 12 (Change over 12 weeks)Description: Change in CGI-I from Baseline to Endpoint
Measure: Clinical Global Impressions-Improvement (CGI-I) Time: Change in CGI-I from Baseline to Week 12 (Change over 12 weeks)Description: The MERS-R is designed to assess three domains of rigid behavior in children and adults with ASD: 1. Behavioral Rigidity (e.g., insistence on sameness, things must be done in his/her way, etc.) 2. Cognitive Rigidity (e.g., special interests, inflexible adherence to rules, etc.) 3. Protest (in response to deviation from rigidity; e.g., verbal objection, tantrum, physical aggression).
Measure: Montefiore Einstein Rigidity Scale-Revised (MERS-R) Time: Change in MERS-R from Baseline to Week 12 (Change over 12 weeks)The objectives of PROVIDE are to: 1. Determine if prophylactic once weekly hydroxychloroquine reduces the incidence of conversion from SARS-2-CoVnasopharyngeal swab negative to positive 2. To determine if weekly prophylactic hydroxychloroquine reduced the severity of COVID-19 symptoms 3. To determine the safety of taking weekly prophylactic hydroxychloroquine
Description: The number of HCW that tested positive for SARS-CoV-2
Measure: Positive for SARS-CoV-2 Time: 8 weeksDescription: The number of HCW that required hospital admission secondary to SARS-CoV-2
Measure: Hospital admissions Time: at any time after first dose to hospital discharge, truncated at 60 daysDescription: The number of HCW that required intensive care unit admission
Measure: Intensive care unit admissions Time: at any time after first dose to hospital discharge, truncated at 60 daysDescription: The number of HCW that required intubation and mechanical ventilation
Measure: Intubation and mechanical ventilation Time: at any time after first dose, truncated at 60 daysDescription: number of days admitted to the ICU
Measure: ICU length of stay Time: from randomization to hospital discharge, truncated at 60 daysDescription: number of days admitted to the hospital
Measure: Hospital length of stay Time: from randomization to hospital discharge, truncated at 60 daysDescription: Death
Measure: Mortality Time: from randomization to 60 daysDescription: Gastrointestinal symptoms (abdominal pain, diarrhea, nausea, vomiting), Hypoglycemia, Abdominal LFTs, Angioedema, Opthalmic (corneal changes, decreased visual acuity, macular degeneration, retinal changes), Bronchospasm
Measure: Incidence of adverse events Time: from randomization to 60 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports